Nefecon and Ambrisentan in IgA Nephropathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 129 participants.

Also called NCT07030894

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 129 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07030894
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07030894. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Nefecon and Ambrisentan in IgA Nephropathy
Acronym
BAIN
Condition
IgA Nephropathy
Condition
Proteinuria
Intervention (Drug)
"Nefecon®","Ambrisentan"
Lead sponsor
The First Hospital of Jilin University (class: other)

Record details

Record id
cardio:ct-nct07030894
Content hash
1342a128c12f851f10d43223ea4aa3018dce35a6b22ab8bc2826c177d8d01916